New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system

1 Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952-7. Search in Google Scholar

2 Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461(1):104-26. Search in Google Scholar

3 Chen SD, Chuang YC, Lin TK, Yang JL. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. Eur J Pharmacol. 2023;938:175439. Search in Google Scholar

4 Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. Search in Google Scholar

5 Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011). 2018 8(1):18-25. Search in Google Scholar

6 Bhalla S, Mehan S, Khan A, Rehman MU. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev. 2022;142:104896. Search in Google Scholar

7 Hölscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Front Synaptic Neurosci. 2022;14:955258. Search in Google Scholar

8 Jerlhag E. Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse. Pharmacol Ther. 2019;196:1-14. Search in Google Scholar

9 Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995; 358(3):219-24. Search in Google Scholar

10 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. Search in Google Scholar

11 Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647-58. Search in Google Scholar

12 Llewellyn-Smith IJ, Reimann F, Gribble FM, Trapp S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neurosci. 2011;180:111-21. Search in Google Scholar

13 Zhu C, Li H, Kong X, Wang Y, Sun T, Wang F. Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder. Front Pharmacol. 2022;13:819470. Search in Google Scholar

14 Hölscher C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol. 2022;179:695-714. Search in Google Scholar

15 During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173e1179. Search in Google Scholar

16 Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1. Mol Metab. 2019;30:72-130. Search in Google Scholar

17 McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31(17):6587-94. Search in Google Scholar

18 Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacol. 2018;136(Pt B):251-9. Search in Google Scholar

19 Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation. 2008;5:19. Search in Google Scholar

20 Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS. 2009;106:1285-90. Search in Google Scholar

21 Yu HY, Sun T, Wang Z, Li H, Xu D, An J et al. Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson’s disease. Neural Regen Res. 2023;18(8):1818-26. Search in Google Scholar

22 K han N, Woodruf f TM, Smith MT. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacol Biochem Behav. 2014;126:13-27. Search in Google Scholar

23 Ammar RA, Mohamed AF, Kamal MM, Safar MM, Abdelkader NF. Neuroprotective Effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome. Inflammopharmacol. 2022;30:919-34. Search in Google Scholar

24 Chiou HYC, Lin MW, Hsiao PJ, Chen CL, Chiao S, Lin TY, Chen YC, et al. Dulaglutide modulates the development of tissue-infiltrating Th1/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system. Int J Mol Sci. 2019;20:1584. Search in Google Scholar

25 Holt MK. Mind affects matter: Hindbrain GLP1 neurons link stress, physiology and behaviour. Exp Physiol. 2021;106(9):1853-62. Search in Google Scholar

26 Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinol. 2016;65:54-66. Search in Google Scholar

27 Komsuoglu Celikyurt I, Mutlu O, Ulak G, Uyar E, Bektaş E, et al. Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes. Med Sci Monit Basic Res. 2014;20:112-7. Search in Google Scholar

28 Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718-31. Search in Google Scholar

29 Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-19. Search in Google Scholar

30 Lupina M, Talarek S, Kotlinska J, Gibula-Tarłowska E, Listos P, Listos J. The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats. Neurochem Int. 2020;133:104616. Search in Google Scholar

31 Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013a;8(7) e69010. Search in Google Scholar

32 Graham DL, Erreger K, Galli A, Stanwood GD. GLP-1 analog attenuates cocaine reward. Mol Psychiatry. 2013;18(9):961-2. Search in Google Scholar

33 Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One. 2013;8(4):e61965. Search in Google Scholar

34 Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21(2):422-37. Search in Google Scholar

35 Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013b;8(10):e77284. Search in Google Scholar

36 Fink-Jensen A, Vilsbøll T. Glucagon-like peptide-1 (GLP-1) analogues: a potential new treatment for alcohol use disorder? Nord J Psychiatry. 2016;70:561-2. Search in Google Scholar